Antileukemic properties of combinations of radiation and malonato(1,2-diaminocyclohexane) platinum(ii) (NSC-224964).
Mean survival times were increased an average of 23, 53 and 61%, when 10, 15, and 20 mg/kg, respectively, of the organoplatinum congener, malonato(1,2-diaminocyclohexane) platinum(II)(NSC-224964), was given as the only treatment modality to BDF1 mice bearing 1-day-old L1210 leukemia. When a single dose of 10 mg/kg was combined with either 300 or 100 R on day 1 only, the anticipated response (ILS = 30 and 38%, respectively) based on the additive effects of the single modalities was surpassed by 26 and 21%, respectively (i.e. extent of therapeutic synergism). When divided doses of radiation (200 R/day x 3 days) were combined with 15 or 20 mg/kg of NSC-224964, survival times were enhanced an average of 15% (extent of synergism) greater than would be expected if these modalities were acting through an additive process(es).
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005069:Evaluation Studies as Topic; D007939:Leukemia L1210 / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010984:Platinum / Q000008:administration & dosage / Q000627:therapeutic use*; D011879:Radiotherapy Dosage
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D009942:Organometallic Compounds; D010984:Platinum